This was consistent with our previous study based on interferon-based therapy (3) and supported the idea that targeting IgM-positive B cells using rituximab (32) is a feasible strategy for the treatment of HCV-associated cryoglobulinemia, even after achieving an SVR, regardless of anti-HCV regimens used. Here, CD40LG is linked to cryoglobulinemia.